设为首页 加入收藏

TOP

ACTEMRA(tocilizumab) injection, solution, concentrate(十)
2014-06-08 23:35:10 来源: 作者: 【 】 浏览:10653次 评论:0
h, pruritus and urticaria. These events were not treatment limiting.

Anaphylaxis

Clinically significant hypersensitivity reactions, including anaphylaxis associated with ACTEMRA and requiring treatment discontinuation were reported in 0.1% (3 out of 2644) in the 24 week, controlled trials and in 0.2% (8 out of 4009) in the all-exposure population. These reactions were generally observed during the second to fourth infusion of ACTEMRA. Appropriate medical treatment should be available for immediate use in the event of a serious hypersensitivity reaction [see Warnings and Precautions (5.5)].

Laboratory Tests

Neutrophils

In the 24 week, controlled clinical studies, decreases in neutrophil counts below 1000 per mm3 occurred in 1.8% and 3.4% of patients in the 4 mg per kg and 8 mg per kg ACTEMRA plus DMARD group, respectively, compared to 0.1% of patients in the placebo plus DMARD group. Approximately half of the instances of ANC below 1000 per mm3 occurred within 8 weeks of starting therapy. Decreases in neutrophil counts below 500 per mm3 occurred in 0.4% and 0.3% of patients in the 4 mg per kg and 8 mg per kg ACTEMRA plus DMARD, respectively, compared to 0.1% of patients in the placebo plus DMARD group. There was no clear relationship between decreases in neutrophils below 1000 per mm3 and the occurrence of serious infections.

In the all-exposure population, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 24 week controlled clinical studies [see Warnings and Precautions (5.3)].

Platelets

In the 24 week, controlled clinical studies, decreases in platelet counts below 100,000 per mm3 occurred in 1.3% and 1.7% of patients on 4 mg per kg and 8 mg per kg ACTEMRA plus DMARD, respectively, compared to 0.5% of patients on placebo plus DMARD, without associated bleeding events.

In the all-exposure population, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 24 week controlled clinical studies [see Warnings and Precautions (5.3)].

Liver Function Tests

Liver enzyme abnormalities are summarized in Table 1. In patients experiencing liver enzyme elevation, modification of treatment regimen, such as reduction in the dose of concomitant DMARD, interruption of ACTEMRA, or reduction in ACTEMRA dose, resulted in decrease or normalization of liver enzymes [see Dosage and Administration (2.3)]. These elevations were not associated with clinically relevant increases in direct bilirubin, nor were they associated with clinical evidence of hepatitis or hepatic insufficiency [see Warnings and Precautions (5.3)].

Table 1 Incidence of Liver Enzyme Abnormalities in the 24 Week Controlled Period of Studies I to V*  ACTEMRA
8 mg per kg MONOTHERAPY
 Methotrexate ACTEMRA
4 mg per kg + DMARDs ACTEMRA
8 mg per kg + DMARDs Placebo + DMARDs
 N = 288
(%) N = 284
(%) N = 774
(%) N = 1582
(%) N = 1170
(%)
ULN = Upper Limit of Normal
*
For a description of these studies, see Section 14, Clinical Studies.
AST (U/L)     
> ULN to 3x ULN 22 26 34 41 17
> 3x ULN to 5x ULN 0.3 2 1 2 0.3
> 5x ULN 0.7 0.4 0.1 0.2 < 0.1
ALT (U/L)     
> ULN to 3x ULN 36 33 45 48 23
> 3x ULN to 5x ULN 1 4 5 5 1
> 5x ULN 0.7 1 1.3 1.5 0.3

In the all-exposure population, the elevations in ALT and AST remained consistent with what was seen in the 24 wee

以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 7 8 9 10 11 12 13 下一页 尾页 10/29/29
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Actemra 下一篇EDARBYCLOR (azilsartan medoxomi..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位